Cassia is an indigenous plant in Africa, Latin America, Northern Australia and Southeast Asia. Several Cassia species are of high commercial and medicinal significance since they are used as spices and in traditional medicines. Currently plants from genus Cassia is in great demand due to their immense medicinal properties. Cassia species have various pharmacological activities such as antibacterial, analgesic, antiinflammatory, antiarthritic, hepatoprotective, antitumor, antifertility, antifungal, antioxidant, antileishmaniatic, antimicrobial, CNS and hypoglycaemic activitiy. Different class of compounds reported from Cassia species are anthraquinones, phenolics, flavonoids, chromenes, terpenes, proanthocyanidins, coumarins, chromones and lignans. The taxonomy and nomenclature of Cassia species are quite complex. It is very difficult to differentiate them due to their overlapping morphological characters and close similarities. This usually leads to misidentification and misinterpretation of the components.
- Presents collection of Ayurvedic features and scientific evidence of most important medicinal plants of Cassia species
- Chemical signatures for identification of Cassia species
- Easy to use analytical procedure for quality control of Cassia species and its products.
Table of Contents
1.1. Introduction. 1.2. Geographical Distribution of genus Cassia. 1.2. Phytography of genus Cassia. 1.3. Phytochemistry of genus Cassia. 1.4. Pharmacological activities of genus Cassia. 1.5. Traditional uses of genus Cassia. 1.6. Introduction of Selected Cassia Species. 2. Qualitative and Quantitative Determination of Bioactive phytochemicals in selected Cassia Species using HPLC-ESI-QTOF-MS and UPLC–ESI–QqQLIT–MS/MS. 2.1. Plant material and chemicals. 2.2. Extraction and sample preparation. 2.3. Preparation of Standard solution. 2.4. HPLC-ESI-QTOF-MS conditions. 2.5. UPLC-ESI-QqQLIT-MS/MS conditions. 2.6. Principal component analysis. 2.7. Optimization of UPLC conditions. 2.8. Optimization of MS/MS conditions. 2.7. Analytical Method Validation. 2.8. Optimization of MS/MS conditions. 2.9. Analytical Method Validation. 2.10. Qualittive Analysis of Cassia Species Samples. 2.11. Quantitative Analysis of Cassia Species Samples. 2.12. Principal Component Analysis to study chemical variations. 3. In-vitro Anti-Proliferative Screening in Selected Cassia Species. 3.1. Plant material. 3.2. Extraction and sample preparation. 3.3. Cell lines and anti-proliferative assay. 3.4. In-vitro anti-proliferative activity evaluation. 4. Bone regeneration effect of Cassia occidentalis Linn. extract and its isolated compounds. 4.1. Bone Healeing Property of Cassia occidentalis. 4.2. Osteoporosis and Arthritis. 4.3. The effects of CO extract fraction and formulation. 4.4. Effects of compounds derived from CO extract. 4. Conclusion.
Dr. Brijesh Kumar is a retired Professor (AcSIR) and Chief Scientist of Sophisticated Analytical Instrument Facility (SAIF) Division, CSIR-Central Drug Research Institute (CDRI), Lucknow, India. He has completed his M. Sc. from Lucknow University and Ph.D from CSIR-CDRI, Lucknow (Dr. Ram. Manohar. Lohia, Avadh University, Faizabad, UP, India). He has to his credit 7 books, 11 book chapters and 147 papers in reputed international journals. His area of research includes applications of mass spectrometry for qualitative and quantitative analysis of molecules for quality control and authentication/standardization of medicinal plants/parts and their herbal formulations
Vikas Bajpai completed his PhD from the Academy of Scientific and Innovative Research (AcSIR), New Delhi, India and carried his research work under supervision of Dr. Brijesh Kumar at CSIR-Central Drug research Institute Lucknow. His research includes development and validation of LC-MS/MS methods for qualitative and quantitative analysis of small molecules of Indian medicinal plants.
Mr. Vikas Kumar Gond is research fellow worked under supervision of Dr. Brijesh Kumar in mass spectrometry laboratory, sophisticated Analytical Instrument Facility at CSIR-Central Drug research Institute, Lucknow. He completed his masters in pharmaceutical chemistry from university of Lucknow. His research includes fingerprinting and characterization of phytopharmaceuticals using LC-MS/MS methods for qualitative and quantitative screening.
Dr. Subhashis Pal is a biologist, born in 1987 in Kolkata, India. He obtained his doctoral degree in 2019 specializing in Endocrinology and bone biology from Jawaharlal Nehru University, Delhi, India. During his Ph.D. tenure, he worked in Central Drug Research Institute, Lucknow, India on the potential bone anabolic role of phosphodiesterase inhibitors. Dr Pal joined Emory University, Atlanta, USA as staff research associate and currently working at Emory University with the effect of gut microbiome on bone health.
Dr. Naibedya Chattopadhyay is a Chief Scientist at CSIR-Central Drug Research Institute. His areas of research are endocrine pharmacology and metabolic bone diseases. Dr. Chattopadhyay has published >200 research articles and 9 patents out of which 5 are licensed to industries.